{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:42Z","timestamp":1792782402206,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t Augsburg","id":[{"id":"https:\/\/ror.org\/03p14d497","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      NUT carcinoma (NUTc) is a\u00a0rare, aggressive squamous carcinoma defined by\n                      <jats:italic>NUTM1<\/jats:italic>\n                      rearrangements. Outcomes in head and neck (H&amp;N) disease are poor, and no uniform treatment standard exists; available evidence largely derives from case reports and small series.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a\u00a0structured narrative review of H&amp;N NUTc with an emphasis on radiotherapy (RT) dose concepts, chemotherapy regimens, and outcome signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Published evidence indicates poor overall survival, particularly in metastatic disease. Long-term remissions have been described in selected patients with non-metastatic disease treated with multimodal approaches combining surgery, multi-agent chemotherapy, and early integrated RT. Across reports, use of RT in first-line management and delivery of definitive-dose RT are repeatedly associated with better outcomes. Evidence for immune checkpoint inhibitors is limited to anecdotal single-patient reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case vignette<\/jats:title>\n                    <jats:p>A\u00a019-year-old man with locally advanced supraglottic NUTc and bilateral cervical nodal disease (M0) presented with dysphagia and otalgia. Following laser debulking and temporary tracheostomy, induction cisplatin\/doxorubicin\/ifosfamide led to a\u00a0complete metabolic response in positron-emission tomography\/computed tomography (PET\/CT) after two cycles of chemotherapy. Definitive PET\/CT-guided intensity-modulated (IM)RT\/image-guided (IG)RT was delivered to 73.2\u202fGy using an accelerated twice-daily schedule (2.0\u202fGy to the planning target volume [PTV] in the morning and 1.6\u202fGy boost to the initial gross target volume [GTV] in the afternoon; \u2265\u202f8-hour interval). Acute toxicity was grade\u00a03 dermatitis and grade\u00a02 mucositis (CTCAE v5.0). After RT, chemotherapy was continued as consolidation and completed with vincristine\/doxorubicin\/ifosfamide (six cycles) due to acute kidney injury. Complete remission is ongoing at &gt;\u202f7\u00a0years, with persistent xerostomia and dysgeusia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In selected non-metastatic H&amp;N NUTc, durable control has been reported with timely systemic therapy plus curative-intent RT, often exceeding 50\u202fGy. This review summarizes dose concepts and case-based systemic regimens and provides a\u00a0comparative table to support individualized treatment planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02552-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:13:09Z","timestamp":1780319589000},"page":"1083-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Head and neck NUT carcinoma\u2014radiotherapy dose, chemotherapy choice, and outcomes: lessons from a\u00a07-year complete remission"],"prefix":"10.1007","volume":"202","author":[{"given":"Lara","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Z\u00e4hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Henning","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Balagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Jehs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Doescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"St\u00fcben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0023-7577","authenticated-orcid":false,"given":"Maria","family":"Neu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"20","key":"2552_CR1","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","volume":"18","author":"DE Bauer","year":"2012","unstructured":"Bauer\u00a0DE, Mitchell\u00a0CM, Strait\u00a0KM, Lathan\u00a0CS, Stelow\u00a0EB, L\u00fcer\u00a0SC et\u00a0al (2012) Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18(20):5773\u20135779","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","volume":"33","author":"H Haack","year":"2009","unstructured":"Haack\u00a0H, Johnson\u00a0LA, Fry\u00a0CJ, Crosby\u00a0K, Polakiewicz\u00a0RD, Stelow\u00a0EB et\u00a0al (2009) Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 33(7):984\u2013991","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"2552_CR3","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1002\/cncr.30242","volume":"122","author":"NG Chau","year":"2016","unstructured":"Chau\u00a0NG, Hurwitz\u00a0S, Mitchell\u00a0CM, Aserlind\u00a0A, Grunfeld\u00a0N, Kaplan\u00a0L et\u00a0al (2016) Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer 122(23):3632\u20133640","journal-title":"Cancer"},{"issue":"3","key":"2552_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00405-018-4882-y","volume":"275","author":"P Giridhar","year":"2018","unstructured":"Giridhar\u00a0P, Mallick\u00a0S, Kashyap\u00a0L, Rath\u00a0GK (2018) Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a\u00a0systematic review and individual patient data analysis of 119 cases. Eur Arch Otorhinolaryngol 275(3):815\u2013821","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2552_CR5","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/OTT.S173056","volume":"12","author":"M Napolitano","year":"2019","unstructured":"Napolitano\u00a0M, Venturelli\u00a0M, Molinaro\u00a0E, Toss\u00a0A (2019) NUT midline carcinoma of the head and neck: current perspectives. Onco Targets Ther 12:3235\u20133244","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2552_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","volume":"203","author":"CA French","year":"2010","unstructured":"French\u00a0CA (2010) NUT midline carcinoma. Cancer Genet Cytogenet 203(1):16\u201320","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2552_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03227-2","volume":"16","author":"N Xiao","year":"2025","unstructured":"Xiao\u00a0N, Lin\u00a0C, Yu\u00a0T, Bi\u00a0F, Tan\u00a0P, Tan\u00a0J et\u00a0al (2025) A case of advanced NUTc of the nasal cavity: case report and review of the literature. Discov Oncol 16(1):1415","journal-title":"Discov Oncol"},{"issue":"4","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/08880018.2017.1363839","volume":"34","author":"S Storck","year":"2017","unstructured":"Storck\u00a0S, Kennedy\u00a0AL, Marcus\u00a0KJ, Teot\u00a0L, Vaughn\u00a0J, Gnekow\u00a0AK et\u00a0al (2017) Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol 34(4):231\u2013237","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"2552_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ccr3.2568","volume":"8","author":"H Zhang","year":"2020","unstructured":"Zhang\u00a0H, Liu\u00a0MH, Zhang\u00a0J, Luo\u00a0SP, Wang\u00a0CB, Zhao\u00a0ZH et\u00a0al (2020) Successful treatment of a case with NUT midline carcinoma in the larynx and review of the literature. Clin Case Rep 8(1):176\u2013181","journal-title":"Clin Case Rep"},{"issue":"1","key":"2552_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2015-x","volume":"13","author":"SK Elkhatib","year":"2019","unstructured":"Elkhatib\u00a0SK, Neilsen\u00a0BK, Sleightholm\u00a0RL, Baine\u00a0MJ, Zhen\u00a0W (2019) A 47-year-old woman with nuclear protein in testis midline carcinoma masquerading as a sinus infection: a case report and review of the literature. J\u00a0Med Case Rep 13(1):57","journal-title":"J Med Case Rep"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7812\/TPP\/20.251","volume":"25","author":"M Pan","year":"2020","unstructured":"Pan\u00a0M, Chang\u00a0JS (2020) Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation. Perm\u00a0J 25:1\u20133","journal-title":"Perm J"},{"issue":"3","key":"2552_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1159\/000526815","volume":"15","author":"M Higashino","year":"2022","unstructured":"Higashino\u00a0M, Kinoshita\u00a0I, Kurisu\u00a0Y, Kawata\u00a0R (2022) Supraglottic NUT Carcinoma: A Case Report and Literature Review. Case Rep Oncol 15(3):980\u2013987","journal-title":"Case Rep Oncol"},{"key":"2552_CR13","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0."},{"issue":"3","key":"2552_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/pro6.1237","volume":"8","author":"Y Zhao","year":"2024","unstructured":"Zhao\u00a0Y, Zhang\u00a0J, Liao\u00a0W, Li\u00a0J, Zhang\u00a0S (2024) NUT carcinoma of the head and neck: A case report and literature review. Precis Radiat Oncol 8(3):138\u2013144","journal-title":"Precis Radiat Oncol"},{"key":"2552_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1368187","volume":"14","author":"X Geng","year":"2024","unstructured":"Geng\u00a0X, Chang\u00a0X, Wang\u00a0X, Li\u00a0S, Han\u00a0G, Song\u00a0Z et\u00a0al (2024) Consolidation immunotherapy following concurrent chemoradiotherapy in a patient with sinonasal NUT carcinoma: a case report. Front Oncol 14:1368187","journal-title":"Front Oncol"},{"key":"2552_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1412070","volume":"14","author":"JKW Ng","year":"2024","unstructured":"Ng\u00a0JKW, Wong\u00a0ECY, So\u00a0TCY, Wong\u00a0RTS (2024) Case report: Long term remission of metastatic sinonasal NUT carcinoma after palliative radiotherapy and immunotherapy in an elderly patient. Front Oncol 14:1412070","journal-title":"Front Oncol"},{"key":"2552_CR17","unstructured":"Haradon JB. NUT carcinoma registry [Available from: https:\/\/nc-registry.org\/clinical-trials\/ Accessed 15 Jan 2026."},{"issue":"1","key":"2552_CR18","volume":"5","author":"SJ Wu","year":"2024","unstructured":"Wu\u00a0SJ, Kim\u00a0JJ, Huang\u00a0Y, Durall\u00a0RT, Becker\u00a0S, Canty\u00a0S et\u00a0al (2024) Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report. JTO Clin Res Rep 5(1):100625","journal-title":"JTO Clin Res Rep"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02552-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:44:55Z","timestamp":1790070295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02552-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02552-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript reports a\u00a0narrative review and includes a\u00a0de-identified single-patient vignette. According to the local ethics committee, de-identified single-patient vignettes do not require formal ethics approval. A\u00a0written \u201cnot required\u201d determination (date: 19.12.2025) is on file and can be provided to the editor on request. The patient provided written informed consent for publication of clinical details and images and signed a\u00a0data privacy consent form.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the clinical details and images was obtained from the patient. A\u00a0copy of the consent is available to the editor on request.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.\u00a0Schulz, M.\u00a0Z\u00e4hringer, K.-H.\u00a0Kahl, N.\u00a0Balagiannis, B.\u00a0Jehs, J.\u00a0Doescher, J.\u00a0Zenk, G.\u00a0St\u00fcben, and M.\u00a0Neu declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}